CEO Stephen Glover said, “ZyVersa is developing Cholesterol Efflux Mediator VAR 200 for treatment of chronic kidney diseases, initially ...

Laila Maidan is a Tech and Investing reporter at MarketWatch. She covers the rapid developments in the sector along with actionable investment recommendations and deep dives into valuations.